April 19, 2021

Impact of Convalescent Plasma Therapy on SARS CoV-2 Antibody Profile in COVID-19 Patients

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• Convalescent plasma (CP) treatment did not predict survival in a longitudinal analysis of plasma samples from hospitalized patients with COVID-19 (n = 16) treated with either CP or standard of care. Among 8 patients who died, marked declines in neutralization titers were observed prior to death, which CP treatment did not reverse. Irrespective of CP treatment, higher antibody affinity to the SARS-CoV-2 prefusion spike was associated with survival, while sustained elevated IgA response was associated with mortality. The authors suggest that more severely-ill patients may be less likely to benefit from CP treatment.

Tang et al. (Apr 2021). Impact of Convalescent Plasma Therapy on SARS CoV-2 Antibody Profile in COVID-19 Patients. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab317